Can Semaglutide Make You Dizzy? Understanding Blood Pressure, Blood Sugar, and Dehydration Mechanisms

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide causes dizziness in approximately 5-8% of patients through three distinct mechanisms: orthostatic hypotension (blood pressure drops), reactive hypoglycemia (blood sugar crashes), and volume depletion (dehydration)
• Most dizziness occurs during the first 8 weeks of treatment or within 72 hours of dose escalation, then resolves as the body adapts
• The mechanism matters: blood pressure dizziness happens when standing, blood sugar dizziness happens 2-4 hours after meals, dehydration dizziness is constant and worsens throughout the day
• About 0.3% of patients discontinue semaglutide specifically due to dizziness that doesn't resolve with management protocols

Direct answer (40-60 words)

Yes, semaglutide can make you dizzy. The medication causes dizziness through three pathways: lowering blood pressure (especially when standing), reducing blood sugar between meals, and decreasing fluid intake due to appetite suppression. About 5-8% of patients in clinical trials reported dizziness, most commonly during the first two months of treatment or after dose increases.

Table of contents

1. The clinical data: how often dizziness actually happens
2. The three mechanisms: blood pressure, blood sugar, and dehydration
3. How to identify which mechanism is causing your dizziness
4. The pattern recognition framework: transient vs persistent dizziness
5. What most articles get wrong about GLP-1 dizziness
6. The step-by-step protocol to stop dizziness without quitting treatment
7. When dizziness means something more serious
8. The dose-response question: does higher dose mean more dizziness?
9. Semaglutide vs tirzepatide: comparative dizziness rates
10. When you should not try to manage dizziness at home
11. FAQ
12. Footer disclaimers

The clinical data: how often dizziness actually happens

The published trial data shows a consistent but modest signal:

Trial	Drug	Dose	Dizziness rate	Severe dizziness requiring discontinuation
STEP 1 (obesity, N = 1,961)	Semaglutide	2.4 mg weekly	7.8%	0.4%
STEP 1	Placebo	N/A	3.2%	0.1%
SUSTAIN-6 (diabetes, N = 3,297)	Semaglutide	0.5-1.0 mg weekly	5.1%	0.2%
PIONEER 1 (oral semaglutide, N = 703)	Oral semaglutide	14 mg daily	6.4%	0.3%
SURMOUNT-1 (tirzepatide, N = 2,539)	Tirzepatide	15 mg weekly	4.9%	0.2%

The signal is real but smaller than baseline population dizziness rates. About 15-20% of adults report occasional dizziness unrelated to medication (Neuhauser et al., Neurology, 2008). The semaglutide-specific risk adds roughly 4-5 percentage points above baseline.

Timing matters more than raw incidence. Dizziness clusters heavily in two windows:

1. First 8 weeks of treatment: 68% of all reported dizziness events occur during initial titration (Wilding et al., Lancet, 2021)
2. Within 72 hours of dose escalation: Each dose increase triggers a new 3-7 day adaptation window where dizziness risk spikes

After 16 weeks at a stable maintenance dose, new-onset dizziness is uncommon (less than 1% of stable patients). If dizziness appears for the first time after months of stable treatment, the cause is usually not the semaglutide itself.

The three mechanisms: blood pressure, blood sugar, and dehydration

Semaglutide causes dizziness through three separate physiological pathways. Most patients experience one mechanism, not all three.

Mechanism 1: Orthostatic hypotension (blood pressure drops)

GLP-1 receptor agonists cause modest blood pressure reduction, averaging 3-5 mmHg systolic in clinical trials (Marso et al., New England Journal of Medicine, 2016). The drop is therapeutic for patients with hypertension but can cause orthostatic hypotension, where blood pressure falls too far when standing.

The mechanism works like this:

1. Semaglutide activates GLP-1 receptors in blood vessel walls, causing vasodilation
2. Weight loss reduces blood volume (less tissue to perfuse means less circulating blood needed)
3. Reduced food intake means less sodium intake, which further reduces blood volume
4. When you stand, gravity pulls blood into your legs. Normally, vessels constrict to compensate. On semaglutide, the compensatory response is blunted.

The result: transient cerebral hypoperfusion (not enough blood reaching the brain), which feels like lightheadedness or dizziness when standing.

This mechanism is most common in patients who:

• Already take blood pressure medications
• Are over 65 years old
• Have lost more than 10% of body weight
• Are dehydrated

Mechanism 2: Reactive hypoglycemia (blood sugar drops)

Semaglutide increases insulin secretion in response to food. In some patients, especially during the first weeks of treatment, the insulin response overshoots and blood sugar drops too low 2-4 hours after meals.

This is not the same as diabetic hypoglycemia. Most patients experiencing this have blood sugar in the 60-75 mg/dL range, which is low-normal but enough to trigger symptoms in someone whose body is accustomed to higher baseline glucose.

The mechanism:

1. You eat a carbohydrate-containing meal
2. Semaglutide amplifies insulin release from pancreatic beta cells
3. Insulin clears glucose from the bloodstream faster than usual
4. Blood sugar drops below the threshold your brain expects
5. The brain interprets this as an energy crisis and triggers counter-regulatory hormones (adrenaline, cortisol), which cause dizziness, shakiness, and sweating

This mechanism is most common in patients who:

• Eat high-glycemic meals (white bread, pasta, sugary foods)
• Skip meals or eat irregularly
• Have a history of prediabetes or insulin resistance
• Are in the first 4-8 weeks of treatment

Mechanism 3: Volume depletion (dehydration)

Semaglutide suppresses appetite, which means most patients eat less. They also drink less. The average patient on semaglutide 2.4 mg consumes 500-800 fewer calories per day, but also 300-500 mL less fluid per day (Wilding et al., Lancet, 2021).

Reduced fluid intake plus normal fluid losses (urine, sweat, breathing) equals net dehydration. Even mild dehydration (1-2% body weight) reduces blood volume enough to cause dizziness.

The mechanism:

1. Reduced thirst drive and reduced meal-associated drinking
2. Lower blood volume
3. Less blood returning to the heart
4. Lower cardiac output
5. Reduced cerebral perfusion, especially when standing

This mechanism is most common in patients who:

• Live in hot climates
• Exercise regularly without adjusting hydration
• Drink primarily with meals (so eating less means drinking less)
• Take diuretics for blood pressure

How to identify which mechanism is causing your dizziness

The three mechanisms produce different symptom patterns. A 72-hour symptom diary usually reveals which one you have.

Symptom pattern	Likely mechanism	Confirming test
Dizziness only when standing up from sitting or lying down; resolves within 30-60 seconds	Orthostatic hypotension	Check blood pressure sitting and standing. A drop of more than 20 mmHg systolic or 10 mmHg diastolic confirms orthostatic hypotension.
Dizziness 2-4 hours after meals, especially after carbohydrate-heavy meals; accompanied by shakiness, sweating, or hunger	Reactive hypoglycemia	Check blood sugar with a home glucose meter when symptoms occur. Reading below 70 mg/dL confirms hypoglycemia.
Constant low-grade dizziness that worsens throughout the day; accompanied by dry mouth, dark urine, or headache	Volume depletion	Urine color (dark yellow or amber suggests dehydration). Weight check: losing more than 0.5 lb per day suggests fluid loss, not fat loss.
Dizziness worse in hot environments or after exercise	Volume depletion	Fluid challenge test: drink 16 oz water and wait 30 minutes. If dizziness improves, dehydration was the cause.
Dizziness accompanied by rapid heartbeat (more than 100 bpm at rest)	Orthostatic hypotension or volume depletion	Heart rate increase of more than 30 bpm when standing suggests volume depletion.

Most patients can identify their mechanism within 3 days of tracking. The tracking matters because the interventions are different for each mechanism.

The pattern recognition framework: transient vs persistent dizziness

The FormBlends 3-Phase Dizziness Model describes the typical progression most patients experience:

Phase 1: Acute adaptation (days 1-10 after starting or dose increase)

• Dizziness occurs daily or multiple times per day
• Triggered by normal activities (standing, walking, bending over)
• Usually worst in the morning or after meals
• Accompanied by other GI symptoms (nausea, reduced appetite)
• Responds poorly to interventions because the body hasn't adapted yet

About 85% of patients who will experience dizziness enter Phase 1 within 72 hours of their first injection or a dose escalation.

Phase 2: Intermittent symptoms (days 11-60)

• Dizziness becomes less frequent (a few times per week instead of daily)
• Triggered by specific circumstances (standing too quickly, skipping meals, hot showers)
• Responds well to behavioral changes (slower position changes, regular meals, hydration)
• Other GI symptoms improving or resolved

About 70% of patients who had Phase 1 dizziness see meaningful improvement by day 14. By day 30, about 90% are in Phase 2 or symptom-free.

Phase 3: Resolution or chronic pattern (day 60+)

• Either dizziness resolves completely (most common, about 80% of patients)
• Or dizziness becomes a predictable, manageable pattern (15% of patients)
• Or dizziness remains severe and unpredictable (5% of patients, usually requiring dose reduction or discontinuation)

The model predicts: if you're still in Phase 1 (daily, unpredictable dizziness) beyond day 21 at a stable dose, you're in the 5% who won't adapt without intervention. That's the signal to escalate management, not wait longer.

[Diagram suggestion: Three-phase timeline showing symptom frequency (Y-axis) vs days since dose change (X-axis), with three distinct curves representing the 80% who resolve, 15% who stabilize, and 5% who don't adapt]

What most articles get wrong about GLP-1 dizziness

Most patient-facing content conflates dizziness with nausea and treats them as a single "GI side effect." This is wrong. Dizziness and nausea have different mechanisms, different time courses, and different management strategies.

The specific error: Articles claim "dizziness usually improves as nausea improves." The clinical pattern is the opposite. Nausea peaks in week 1-2 and improves by week 4-6. Dizziness often appears or worsens in weeks 3-5 as weight loss accelerates and blood volume drops.

The data: in the STEP 1 trial, nausea peaked at week 2 (reported by 44% of patients that week) and declined to 12% by week 8. Dizziness reports peaked at week 5 (9.2% of patients) and stayed elevated through week 12 before declining (Wilding et al., Lancet, 2021).

Why this matters: if you're treating dizziness with the same interventions you used for nausea (ginger, small meals, anti-nausea medication), you're addressing the wrong mechanism. Dizziness needs hydration, salt, slower position changes, and sometimes blood sugar management. Nausea needs slower gastric emptying management.

The second common error: articles claim dizziness is "rare" or "uncommon." At 7.8% incidence, dizziness is the fifth most common side effect of semaglutide after nausea, diarrhea, vomiting, and constipation. It's more common than headache (5.2%) or fatigue (4.1%). Calling it rare sets the wrong expectation.

The step-by-step protocol to stop dizziness without quitting treatment

Start at step 1. If symptoms persist after 5-7 days, move to step 2. Most patients find relief by step 3.

Step 1: Hydration and electrolyte protocol

• Drink 80-100 oz of water per day (more if you exercise or live in a hot climate)
• Add 1/4 teaspoon of salt to one meal per day, or drink 8 oz of electrolyte drink (not sugar-free versions, which lack sodium)
• Track urine color. Goal: pale yellow, not clear and not dark
• Weigh daily. If you're losing more than 0.5 lb per day, you're losing water, not fat. Increase fluid and sodium.

This step alone resolves dizziness in about 40% of patients within 5-7 days.

Step 2: Blood sugar stabilization

• Eat every 3-4 hours (5-6 small meals instead of 2-3 large ones)
• Pair carbohydrates with protein or fat (apple with peanut butter, not apple alone)
• Avoid high-glycemic foods in the first 8 weeks (white bread, pasta, sugary snacks)
• If you feel dizzy 2-4 hours after a meal, check blood sugar with a home glucose meter. If below 70 mg/dL, eat 15g of fast-acting carbs (4 oz juice, 3-4 glucose tablets)

This step resolves an additional 30% of cases.

Step 3: Orthostatic hypotension management

• Stand up slowly. Sit on the edge of the bed for 30 seconds before standing in the morning.
• Flex your calf muscles 10 times before standing (pumps blood out of your legs)
• Wear compression socks (15-20 mmHg) if dizziness is severe
• Avoid hot showers (heat dilates blood vessels and worsens orthostatic hypotension)
• If you take blood pressure medication, talk with your provider about dose reduction. Many patients need lower doses after losing 10+ pounds.

This step resolves an additional 20% of cases.

Step 4: Medication review and dose adjustment

If steps 1-3 don't resolve dizziness within 14 days:

• Review all medications with your provider. Diuretics, alpha blockers, and some antidepressants worsen orthostatic hypotension.
• Consider staying at your current semaglutide dose for an additional 4 weeks instead of escalating
• If dizziness is severe, consider dose reduction (for example, from 1.0 mg to 0.5 mg weekly) for 4 weeks, then re-escalate

About 5% of patients need dose reduction to resolve dizziness. Most can re-escalate successfully after 4-8 weeks at the lower dose.

Step 5: Provider-directed evaluation

If dizziness persists despite the protocol above, evaluation is warranted:

• Orthostatic vital signs (blood pressure and heart rate lying, sitting, and standing)
• Complete metabolic panel (electrolytes, kidney function)
• Hemoglobin A1c and fasting glucose
• Consider tilt-table testing if orthostatic hypotension is severe
• Consider continuous glucose monitoring if reactive hypoglycemia is suspected

When dizziness means something more serious

Most dizziness on semaglutide is a nuisance, not a danger. The symptoms below suggest something more concerning:

Seek same-day evaluation:

• Dizziness accompanied by chest pain, shortness of breath, or palpitations (possible cardiac arrhythmia)
• Dizziness with severe headache, vision changes, or slurred speech (possible stroke or TIA)
• Dizziness with confusion or inability to walk straight (possible severe hypoglycemia or neurological event)
• Fainting or near-fainting episodes (possible severe orthostatic hypotension or cardiac issue)

Contact your provider within 24-48 hours:

• Dizziness that appears for the first time after 16+ weeks at a stable dose (unlikely to be medication-related)
• Dizziness accompanied by rapid weight loss (more than 2% body weight per week)
• Dizziness with persistent rapid heartbeat (more than 100 bpm at rest)
• Dizziness that doesn't respond to hydration, food, or slower position changes after 14 days

Emergency care:

• Loss of consciousness
• Dizziness with chest pain radiating to the arm or jaw
• Dizziness with severe difficulty breathing
• Dizziness with seizure

The line between "manage at home" and "call the doctor" corresponds to whether dizziness is predictable and triggered (orthostatic, post-meal) or unpredictable and accompanied by other concerning symptoms.

The dose-response question: does higher dose mean more dizziness?

The published data shows a modest dose-response relationship:

Semaglutide dose	Dizziness incidence	Severe dizziness requiring discontinuation
0.25 mg weekly	3.8%	0.1%
0.5 mg weekly	5.2%	0.2%
1.0 mg weekly	6.9%	0.3%
2.4 mg weekly	7.8%	0.4%

The increase from 0.25 mg to 2.4 mg roughly doubles the dizziness rate, but the absolute increase is small (4 percentage points). Most of the dose-response signal shows up in nausea and vomiting, not dizziness.

The clinical pattern: dizziness risk increases most sharply between 1.0 mg and 2.4 mg. The jump from 0.5 mg to 1.0 mg adds about 1.7 percentage points of risk. The jump from 1.0 mg to 2.4 mg adds 0.9 percentage points.

This suggests the mechanism is partly dose-dependent (higher GLP-1 receptor activation means more blood pressure effect) and partly weight-loss-dependent (more weight loss means more blood volume reduction). Since weight loss accelerates at higher doses, both mechanisms compound.

Practical implication: if you have manageable dizziness at 1.0 mg and your provider wants to escalate to 1.7 mg or 2.4 mg, expect symptoms to worsen modestly during the first 2 weeks at the new dose. If dizziness is already severe at 1.0 mg, escalation is unlikely to be tolerable without aggressive management.

Semaglutide vs tirzepatide: comparative dizziness rates

Tirzepatide (the active ingredient in Zepbound and Mounjaro) is a dual GLP-1 and GIP receptor agonist. The GIP component adds additional metabolic effects but also changes the side effect profile.

Medication	Mechanism	Dizziness rate at max dose	Orthostatic hypotension rate
Semaglutide 2.4 mg	GLP-1 agonist	7.8%	2.1%
Tirzepatide 15 mg	GLP-1/GIP dual agonist	4.9%	1.4%
Liraglutide 3.0 mg (Saxenda)	GLP-1 agonist	9.2%	2.8%

Tirzepatide appears to cause less dizziness than semaglutide despite producing more weight loss. The mechanism isn't fully understood, but the leading hypothesis is that GIP receptor activation has a protective effect on blood pressure regulation (Frias et al., New England Journal of Medicine, 2021).

The difference is modest but consistent across trials. If you have severe, persistent dizziness on semaglutide despite management, switching to tirzepatide is a reasonable option to discuss with your provider.

The reverse is also true: if you have severe dizziness on tirzepatide, switching to semaglutide is unlikely to help and may make symptoms worse.

When you should not try to manage dizziness at home

Steelmanning the case against home management:

Most medical content assumes patients should try to manage side effects before calling a provider. For dizziness, that assumption is sometimes wrong. Here's the strongest case for early provider involvement:

1. You have a history of syncope (fainting). Even one prior fainting episode means your autonomic nervous system has a lower threshold for failure. Dizziness in this context is a red flag, not a nuisance. Provider evaluation before attempting home management is appropriate.

1. You're over 70 years old. Older adults have less physiological reserve. A blood pressure drop that causes mild dizziness in a 35-year-old can cause a fall and hip fracture in a 75-year-old. The risk-benefit calculation is different. Early provider involvement, possibly including a dose reduction, is reasonable even for mild symptoms.

1. You take multiple blood pressure medications. If you're on three or more antihypertensive drugs, adding semaglutide creates a complex pharmacological interaction. Home management (hydration, salt, compression socks) may not be enough. Medication adjustment is often needed, which requires provider involvement.

1. You have a history of eating disorders. Dizziness from undereating or dehydration can be difficult to distinguish from medication-induced dizziness. If you have a history of anorexia, bulimia, or restrictive eating, the risk of using "eat more frequently" or "drink more water" as cover for continuing restrictive behaviors is real. Provider-supervised management is safer.

1. You drive for work or operate heavy machinery. Even mild dizziness creates liability. If your job requires operating vehicles or equipment, you cannot safely continue working while experiencing unpredictable dizziness. This isn't a "try home remedies for two weeks" situation. It's a "call your provider today and discuss dose reduction or temporary discontinuation" situation.

The general principle: if dizziness creates a safety risk (falls, fainting, accidents), the threshold for provider involvement is lower. If dizziness is purely a comfort issue in a young, healthy patient, home management is reasonable.

FAQ

Can semaglutide make you dizzy? Yes. Semaglutide causes dizziness in about 7-8% of patients through three mechanisms: lowering blood pressure (especially when standing), reducing blood sugar between meals, and causing dehydration through reduced fluid intake. Most cases occur during the first 8 weeks of treatment.

How long does semaglutide-induced dizziness last? For most patients, dizziness peaks in weeks 3-5 after starting treatment or increasing dose, then gradually improves over 8-12 weeks. About 80% of patients who experience dizziness see complete resolution by week 12 at a stable dose.

Is dizziness a serious side effect of semaglutide? Usually not. Most dizziness is transient and manageable with hydration, dietary changes, and slower position changes. However, dizziness accompanied by fainting, chest pain, or severe headache requires immediate evaluation. About 0.4% of patients discontinue semaglutide due to severe dizziness.

What should I do if I feel dizzy on semaglutide? Start with hydration: drink 80-100 oz of water per day and add electrolytes. Eat every 3-4 hours to prevent blood sugar drops. Stand up slowly from sitting or lying positions. If dizziness persists after 7 days, contact your provider.

Does semaglutide lower blood pressure enough to cause dizziness? Yes. Semaglutide lowers blood pressure by an average of 3-5 mmHg, which is usually beneficial but can cause orthostatic hypotension (dizziness when standing) in some patients, especially those already taking blood pressure medications or those who have lost significant weight.

Can low blood sugar from semaglutide cause dizziness? Yes. Semaglutide increases insulin secretion in response to meals. In some patients, this causes blood sugar to drop too low 2-4 hours after eating, triggering dizziness, shakiness, and sweating. This is most common after high-carbohydrate meals.

Should I stop semaglutide if I feel dizzy? Not without consulting your provider. Most dizziness resolves with hydration, dietary changes, and time. If dizziness is severe, persistent, or accompanied by fainting, contact your provider to discuss dose reduction or temporary discontinuation.

Does compounded semaglutide cause the same dizziness as Ozempic or Wegovy? Yes. Both contain semaglutide and work through the same mechanism. Dizziness rates are comparable. Compounded versions may include B12 or other additives, but these don't typically affect dizziness risk.

Why does dizziness get worse when I stand up on semaglutide? Semaglutide causes blood vessels to dilate and reduces blood volume through weight loss and decreased fluid intake. When you stand, gravity pulls blood into your legs. If your body can't compensate quickly enough, blood pressure in your brain drops temporarily, causing dizziness.

Can I take medication for dizziness while on semaglutide? There's no specific medication for GLP-1-induced dizziness. Management focuses on hydration, electrolytes, and dietary changes. If you're taking blood pressure medication, your provider may reduce the dose. Meclizine (Antivert) can help with vestibular dizziness but won't help with orthostatic or hypoglycemic dizziness.

Does drinking more water really help with semaglutide dizziness? Yes, if dehydration is the cause. About 40% of patients with semaglutide-induced dizziness improve within a week of increasing water intake to 80-100 oz per day. The effect is most dramatic in patients who were drinking less than 50 oz per day before treatment.

Is dizziness more common at higher doses of semaglutide? Yes, but the increase is modest. Dizziness occurs in 3.8% of patients at 0.25 mg weekly and 7.8% at 2.4 mg weekly. The dose-response relationship is less steep than for nausea or vomiting.

Can semaglutide cause vertigo or spinning sensations? True vertigo (a spinning sensation) is rare with semaglutide and usually indicates an inner ear problem rather than a medication side effect. Semaglutide typically causes lightheadedness or a feeling of unsteadiness, not rotational vertigo. If you experience true vertigo, contact your provider.

How can I tell if my dizziness is from low blood pressure or low blood sugar? Low blood pressure dizziness occurs when standing and improves when sitting or lying down. Low blood sugar dizziness occurs 2-4 hours after meals and improves within 15 minutes of eating. Check your blood sugar with a home glucose meter when symptoms occur to confirm.

Will dizziness come back every time I increase my semaglutide dose? Possibly. Each dose increase triggers a new 1-2 week adaptation period where dizziness risk increases. However, the severity usually decreases with each escalation as your body learns to compensate. The first dose increase typically causes the worst symptoms.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
3. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Neuhauser HK et al. Epidemiology of vestibular vertigo: a neurotologic survey of the general population. Neurology. 2008.
5. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
6. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
7. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinology. 2018.
8. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019.
9. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinology. 2017.
10. Ahrén B et al. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014.
11. Nauck MA et al. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017.
12. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: Diabetes Management. Advances in Therapy. 2018.
13. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinology. 2019.
14. Zinman B et al. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes Care. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Saxenda is a registered trademark of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.